The Racing Drug & Trials Association announced today that RegVet CE 2022, a veterinary continuing education program for racing regulated veterinarians, will be held at Churchill Downs March 21 to 22.
This course will present 18 hours of continuing education through lectures, interactive sessions, and practice. The 2022 theme is Infectious Diseases and Horse Movement and will feature internationally recognized experts including Dr. Peter Timoney FRCVS (University of Kentucky); David Horohov, PhD (University of Kentucky); Maureen Long, DVM, PhD, DACVIM (University of Florida); and Laurie Beard, DVM, DACVIM (Kansas State University).
RegVet CE, the first and only conference of its kind, presented at Keeneland in 2018. The meeting drew veterinarians from across North America, the UK, Australia, Hong Kong, Chile and the Caribbean.
This educational conference was developed for regulated and official racing veterinarians by the Association of Drugs and Trials Racing. Through lectures, labs, and interactive, hands-on sessions, the conference provides training that is directly related to the duties and responsibilities of racing governing body veterinarians in the conservation of racing. protect the health and welfare of racehorses and support the integrity of the competition.
RMTC chief executive officer, Dr Mary Scollay, said: “Being an international source of quality education for specialist veterinarians in such a short space of time has attested to the work of so many. people in organizing these events. “We are grateful to all of our stakeholder sponsors who have invested in our regulated veterinarians – and the safety and integrity of their sport. me – by supporting this program.”
Registration will open on January 3, 2022. Reference RMTC RegVet CE website for updates and more information.
Industry News – To support purebred industry organizations, BloodHorse publishes industry-related newsletters. Unedited releases by Blood-Horse. If you have any questions please contact the organization that produced the newsletter as directed in the newsletter.
